{"component": "clause", "props": {"groups": [{"samples": [{"hash": "eAVjsvfA4Gv", "uri": "/contracts/eAVjsvfA4Gv#development-data", "label": "Exclusive License Agreement (Relief Therapeutics Holding SA)", "score": 35.3271713257, "published": true}, {"hash": "yq022G54Eu", "uri": "/contracts/yq022G54Eu#development-data", "label": "Exclusive License Agreement (Acer Therapeutics Inc.)", "score": 34.6618766785, "published": true}], "snippet": "If this Agreement is terminated for any reason, Relief shall, for a period of ninety (90) days following the effective date of such termination and upon Acer\u2019s request, provide Acer access to and transfer all Development Data in its possession to Acer as of the effective date of such termination.", "snippet_links": [{"key": "this-agreement", "type": "clause", "offset": [3, 17]}, {"key": "for-any-reason", "type": "clause", "offset": [32, 46]}, {"key": "period-of", "type": "definition", "offset": [68, 77]}, {"key": "date-of", "type": "clause", "offset": [119, 126]}, {"key": "access-to", "type": "definition", "offset": [182, 191]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [252, 276]}], "size": 4, "hash": "ccc6c4b47e4c32d808d671302896a25c", "id": 1}, {"samples": [{"hash": "2pRa9THPkRz", "uri": "/contracts/2pRa9THPkRz#development-data", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 28.950717926, "published": true}, {"hash": "jjBdizJCLoe", "uri": "/contracts/jjBdizJCLoe#development-data", "label": "License, Development and Commercialization Agreement", "score": 26.226556778, "published": true}], "snippet": "(a) Ownership and Disclosure. FibroGen shall solely own all data, records and reports generated by or on behalf of either Party in the conduct of Development activities under this Agreement (collectively, the \u201cDevelopment Data\u201d), and AstraZeneca hereby assigns, and shall assign, to FibroGen, all of its right, title and interest in and to the Development Data. Each Party shall provide access to and, where practical, copies of the Development Data it (or its Affiliates or Sublicensees, or Third Parties acting on their behalf) generates to the other Party promptly upon receipt or development thereof, including nonclinical and clinical data (including raw data), analysis, reports and protocols. With respect to any data, records and reports, including nonclinical and clinical data (including raw data), analysis, reports and protocols, generated by or on behalf of FibroGen [ * ]\u201d), the following shall apply. [ * ]. AstraZeneca shall reimburse FibroGen for any translation costs, costs for photocopying or other similar administrative expenses incurred by FibroGen in connection with providing access to the [ * ]. Each Party will reasonably respond to the other Party\u2019s request for access to and questions about the Development Data and Astellas Data. Such Development Data will be provided in electronic form if requested by the other Party or reasonably convertible to such electronic form.", "snippet_links": [{"key": "ownership-and-disclosure", "type": "clause", "offset": [4, 28]}, {"key": "records-and-reports", "type": "definition", "offset": [66, 85]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [96, 114]}, {"key": "either-party", "type": "definition", "offset": [115, 127]}, {"key": "activities-under-this-agreement", "type": "clause", "offset": [158, 189]}, {"key": "title-and-interest", "type": "clause", "offset": [311, 329]}, {"key": "the-development", "type": "clause", "offset": [340, 355]}, {"key": "provide-access", "type": "clause", "offset": [379, 393]}, {"key": "where-practical", "type": "clause", "offset": [402, 417]}, {"key": "copies-of-the", "type": "clause", "offset": [419, 432]}, {"key": "third-parties", "type": "definition", "offset": [492, 505]}, {"key": "other-party", "type": "clause", "offset": [547, 558]}, {"key": "promptly-upon-receipt", "type": "clause", "offset": [559, 580]}, {"key": "clinical-data", "type": "definition", "offset": [631, 644]}, {"key": "raw-data", "type": "definition", "offset": [656, 664]}, {"key": "with-respect-to", "type": "clause", "offset": [700, 715]}, {"key": "translation-costs", "type": "clause", "offset": [968, 985]}, {"key": "expenses-incurred", "type": "definition", "offset": [1042, 1059]}, {"key": "in-connection-with", "type": "clause", "offset": [1072, 1090]}, {"key": "access-to-the", "type": "clause", "offset": [1101, 1114]}, {"key": "each-party-will", "type": "clause", "offset": [1122, 1137]}, {"key": "respond-to", "type": "definition", "offset": [1149, 1159]}, {"key": "request-for-access", "type": "clause", "offset": [1178, 1196]}, {"key": "electronic-form", "type": "definition", "offset": [1302, 1317]}, {"key": "requested-by", "type": "definition", "offset": [1321, 1333]}], "size": 4, "hash": "67c34ea8b1fbd4c120a5578ed0646430", "id": 2}, {"samples": [{"hash": "kRA06mZnXJM", "uri": "/contracts/kRA06mZnXJM#development-data", "label": "Covid Collaboration and License Agreement", "score": 32.6830863953, "published": true}, {"hash": "6P8uO394Fqf", "uri": "/contracts/6P8uO394Fqf#development-data", "label": "Covid Collaboration and License Agreement (CureVac N.V.)", "score": 32.3182754517, "published": true}], "snippet": "Subject to Section 11, the Development Data shall be treated as Confidential Information of the Party or Parties owning it. Each Party may use, and allow its Affiliates to use, the Development Data for the purpose of obtaining adequate protection and prosecution of their respective Know-How and Patent Rights, or as provided for otherwise in accordance with this Agreement, provided that in each case it provides the other Party with prior written notice of its intent to use the Development Data for such purpose. The other Party may, within a reasonable time following receipt of such notice, request the notifying Party to delay the use of the Development Data, in order to safeguard the protection and prosecution of other Know-How and Patent Rights. Following such request, the Parties shall cooperate in good faith to align the protection and prosecution of each Party\u2019s Know-How and Patent Rights. For the avoidance of doubt, the terms and conditions of this Section 9 shall govern the intellectual property rights of the Parties in the Development Data.", "snippet_links": [{"key": "subject-to-section-11", "type": "clause", "offset": [0, 21]}, {"key": "the-development", "type": "clause", "offset": [23, 38]}, {"key": "confidential-information-of", "type": "clause", "offset": [64, 91]}, {"key": "party-or-parties", "type": "definition", "offset": [96, 112]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [198, 216]}, {"key": "adequate-protection", "type": "clause", "offset": [227, 246]}, {"key": "patent-rights", "type": "definition", "offset": [296, 309]}, {"key": "in-accordance-with", "type": "definition", "offset": [340, 358]}, {"key": "this-agreement", "type": "clause", "offset": [359, 373]}, {"key": "provided-that", "type": "clause", "offset": [375, 388]}, {"key": "each-case", "type": "definition", "offset": [392, 401]}, {"key": "other-party", "type": "clause", "offset": [418, 429]}, {"key": "notice-of", "type": "definition", "offset": [449, 458]}, {"key": "intent-to-use", "type": "clause", "offset": [463, 476]}, {"key": "reasonable-time", "type": "clause", "offset": [546, 561]}, {"key": "receipt-of", "type": "clause", "offset": [572, 582]}, {"key": "notifying-party", "type": "clause", "offset": [608, 623]}, {"key": "in-order-to", "type": "clause", "offset": [666, 677]}, {"key": "the-parties-shall", "type": "clause", "offset": [780, 797]}, {"key": "in-good-faith", "type": "definition", "offset": [808, 821]}, {"key": "of-each-party", "type": "clause", "offset": [862, 875]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [906, 932]}, {"key": "the-terms-and-conditions-of-this", "type": "clause", "offset": [934, 966]}, {"key": "section-9", "type": "definition", "offset": [967, 976]}, {"key": "intellectual-property-rights-of-the-parties", "type": "clause", "offset": [994, 1037]}], "size": 4, "hash": "65a2e4d854b55f08caa6c9d3566b9a28", "id": 3}, {"samples": [{"hash": "jjFXUvvjJ7T", "uri": "/contracts/jjFXUvvjJ7T#development-data", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 31.8446273804, "published": true}, {"hash": "cl63x8GGuIk", "uri": "/contracts/cl63x8GGuIk#development-data", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 31.5954818726, "published": true}, {"hash": "JoyD82EnjY", "uri": "/contracts/JoyD82EnjY#development-data", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 25.8076667786, "published": true}], "snippet": "(a) Ownership and Disclosure. FibroGen Cayman shall solely own all data, records and reports generated by or on behalf of either Party in the conduct of Development activities under this Agreement (collectively, the \u201cDevelopment Data\u201d), and AstraZeneca hereby assigns, and shall assign, to FibroGen Cayman, all of its right, title and interest in and to the Development Data. Each Party shall provide access to and, where practical, copies of the Development Data it (or its Affiliates or Sublicensees, or Third Parties acting on their behalf) generates to the other Party promptly upon receipt or development thereof, including nonclinical and clinical data (including raw data), analysis, reports and protocols. Each Party will reasonably respond to the other Party\u2019s request for access to and questions about the Development Data. Such Development Data will be provided in electronic form if requested by the other Party or reasonably convertible to such electronic form.", "snippet_links": [{"key": "ownership-and-disclosure", "type": "clause", "offset": [4, 28]}, {"key": "records-and-reports", "type": "definition", "offset": [73, 92]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [103, 121]}, {"key": "either-party", "type": "definition", "offset": [122, 134]}, {"key": "activities-under-this-agreement", "type": "clause", "offset": [165, 196]}, {"key": "title-and-interest", "type": "clause", "offset": [325, 343]}, {"key": "the-development", "type": "clause", "offset": [354, 369]}, {"key": "access-to", "type": "definition", "offset": [401, 410]}, {"key": "where-practical", "type": "clause", "offset": [416, 431]}, {"key": "copies-of-the", "type": "clause", "offset": [433, 446]}, {"key": "third-parties", "type": "definition", "offset": [506, 519]}, {"key": "other-party", "type": "clause", "offset": [561, 572]}, {"key": "promptly-upon-receipt", "type": "clause", "offset": [573, 594]}, {"key": "clinical-data", "type": "definition", "offset": [645, 658]}, {"key": "raw-data", "type": "definition", "offset": [670, 678]}, {"key": "each-party-will", "type": "clause", "offset": [714, 729]}, {"key": "respond-to", "type": "definition", "offset": [741, 751]}, {"key": "request-for-access", "type": "clause", "offset": [770, 788]}, {"key": "electronic-form", "type": "definition", "offset": [876, 891]}, {"key": "requested-by", "type": "definition", "offset": [895, 907]}], "size": 3, "hash": "e6c41697712b5c938db5e31239789c14", "id": 4}, {"samples": [{"hash": "6M5V7lxzezE", "uri": "/contracts/6M5V7lxzezE#development-data", "label": "License Agreement (Rhythm Pharmaceuticals, Inc.)", "score": 28.7316913605, "published": true}, {"hash": "1rKv9B8s7Rp", "uri": "/contracts/1rKv9B8s7Rp#development-data", "label": "License Agreement (Rhythm Pharmaceuticals, Inc.)", "score": 28.6769332886, "published": true}, {"hash": "4GHMsY5Y4S8", "uri": "/contracts/4GHMsY5Y4S8#development-data", "label": "License Agreement (Rhythm Pharmaceuticals, Inc.)", "score": 27.2614650726, "published": true}], "snippet": "To the extent permitted by law and subject to the terms and conditions set forth in this Section 3.7, Rhythm grants Camurus, its Affiliates and licensees the right to cross-reference those portions of any Development Data and regulatory filings, including INDs, NDAs and Regulatory Approvals, Controlled by Rhythm or its Affiliates that are directly related to safety and CMC aspects of the FC Technology and do not include information concerning the Drug and that have been submitted to the FDA or any other applicable Regulatory Authorities, in each case only to the extent that such right to cross-reference, is necessary or useful for Camurus\u2019, its Affiliates\u2019 and licensees\u2019 regulatory filings for other products that utilize the FC Technology, provided that such other products do not consist of a Product or a Competing Product. Camurus shall provide Rhythm with at least thirty (30) days advanced written notice of the regulatory agency and division which is receiving the cross-reference filing, before Camurus or any of its Affiliates or licensees exercises any right of cross-reference as contemplated under the foregoing provisions of this paragraph. Rhythm shall give Camurus, its Affiliates and licensees reasonable access and right to use (including the right to copy where reasonably required) to a copy of those portions of the Development Data, IND, NDA or Regulatory Approvals Controlled by Rhythm, its Affiliates or its Sublicensees that are directly related to safety and CMC aspects of the FC Technology and do not include information concerning the Drug , in each case only to the extent that such right of reasonable access and use is necessary or useful for development or regulatory filings for products that utilize the FC Technology and do not consist of a Product or a Competing Product. Camurus shall be responsible for reimbursement to Rhythm of any costs on an hourly fee basis incurred in connection with the provision of access to any data by Rhythm pursuant to this Section 3.7, including the costs of segregating data that relates solely to the FC Technology. Such costs shall be calculated on an hourly fee basis. Camurus shall provide Rhythm, its Affiliates, Sublicensees with a right of cross-reference, a right of reasonable access and a right to use the development data and regulatory filings and regulatory approvals that Camurus or its Affiliates Control that are directly related to the FC Technology and that do not include information concerning any active pharmaceutical ingredient under development by Camurus or its Affiliates or licensees or sublicensees, in each case only to the extent that such right to cross-reference, such right of reasonable access and such right of use is necessary or useful for regulatory filings for the Product made or to be made by Rhythm, its Affiliates or Sublicensees. Rhythm shall provide Camurus with at least thirty (30) days advanced written notice of the regulatory agency and division which is receiving the cross-reference filing, before Rhythm or any of its Affiliates or Sublicensees exercises any right of cross-reference as contemplated under the foregoing provisions of this paragraph. Rhythm shall be responsible for reimbursement to Camurus of any costs incurred in connection with the provision of access to any data by Camurus pursuant to this Section 3.7, including the costs of segregating data that relates solely to the FC Technology. Such costs shall be calculated on an hourly fee basis. It is noted that Camurus is currently negotiating sublicensing rights under its license agreement with [ ]* to [ ]* generated know-how pertaining to the FC Technology and that do not include information concerning any active pharmaceutical ingredient under development by [ ]* or its Affiliates. The Parties agree that until Camurus succeeds in securing such sublicensing rights from [ ]* under such license agreement that would permit Camurus to grant to Rhythm rights to such know-how as provided in Section 3.7, Camurus shall not sublicense or otherwise grant or provide the rights granted by Rhythm to Camurus in this Section 3.7 or Section 2.4 to [ ]* or its Affiliates.", "snippet_links": [{"key": "to-the-extent-permitted-by-law", "type": "clause", "offset": [0, 30]}, {"key": "the-terms-and-conditions", "type": "definition", "offset": [46, 70]}, {"key": "section-37", "type": "clause", "offset": [89, 100]}, {"key": "directly-related-to", "type": "definition", "offset": [341, 360]}, {"key": "safety-and", "type": "clause", "offset": [361, 371]}, {"key": "fc-technology", "type": "definition", "offset": [391, 404]}, {"key": "concerning-the", "type": "clause", "offset": [436, 450]}, {"key": "the-fda", "type": "clause", "offset": [488, 495]}, {"key": "applicable-regulatory-authorities", "type": "definition", "offset": [509, 542]}, {"key": "each-case", "type": "definition", "offset": [547, 556]}, {"key": "such-right", "type": "definition", "offset": [581, 591]}, {"key": "for-other-products", "type": "clause", "offset": [699, 717]}, {"key": "provided-that", "type": "clause", "offset": [750, 763]}, {"key": "consist-of", "type": "clause", "offset": [791, 801]}, {"key": "competing-product", "type": "definition", "offset": [817, 834]}, {"key": "notice-of-the", "type": "clause", "offset": [913, 926]}, {"key": "regulatory-agency", "type": "definition", "offset": [927, 944]}, {"key": "the-foregoing-provisions-of-this", "type": "clause", "offset": [1119, 1151]}, {"key": "access-and-right-to-use", "type": "clause", "offset": [1230, 1253]}, {"key": "right-to-copy", "type": "clause", "offset": [1269, 1282]}, {"key": "where-reasonably-required", "type": "clause", "offset": [1283, 1308]}, {"key": "a-copy-of", "type": "clause", "offset": [1313, 1322]}, {"key": "the-development", "type": "clause", "offset": [1341, 1356]}, {"key": "access-and-use", "type": "definition", "offset": [1641, 1655]}, {"key": "for-development", "type": "clause", "offset": [1679, 1694]}, {"key": "for-products", "type": "clause", "offset": [1717, 1729]}, {"key": "responsible-for", "type": "clause", "offset": [1834, 1849]}, {"key": "fee-basis", "type": "clause", "offset": [1900, 1909]}, {"key": "in-connection-with", "type": "clause", "offset": [1919, 1937]}, {"key": "access-to", "type": "definition", "offset": [1955, 1964]}, {"key": "pursuant-to", "type": "definition", "offset": [1984, 1995]}, {"key": "costs-of", "type": "definition", "offset": [2028, 2036]}, {"key": "regulatory-filings-and-regulatory-approvals", "type": "clause", "offset": [2316, 2359]}, {"key": "active-pharmaceutical-ingredient", "type": "definition", "offset": [2497, 2529]}, {"key": "under-development", "type": "definition", "offset": [2530, 2547]}, {"key": "right-of-use", "type": "clause", "offset": [2716, 2728]}, {"key": "the-product", "type": "definition", "offset": [2779, 2790]}, {"key": "costs-incurred", "type": "definition", "offset": [3246, 3260]}, {"key": "sublicensing-rights", "type": "clause", "offset": [3544, 3563]}, {"key": "license-agreement", "type": "clause", "offset": [3574, 3591]}, {"key": "pertaining-to", "type": "definition", "offset": [3629, 3642]}, {"key": "the-parties-agree-that", "type": "clause", "offset": [3790, 3812]}, {"key": "granted-by", "type": "definition", "offset": [4079, 4089]}, {"key": "section-24", "type": "clause", "offset": [4131, 4142]}], "size": 3, "hash": "1a268b2e4afe7adcf994e9ee6e93e32d", "id": 5}, {"samples": [{"hash": "kW52oL9HxEi", "uri": "/contracts/kW52oL9HxEi#development-data", "label": "Commercialization and License Agreement (Aptalis Pharma Inc)", "score": 23.3189601898, "published": true}, {"hash": "lJ2jX87fPrL", "uri": "/contracts/lJ2jX87fPrL#development-data", "label": "Commercialization and License Agreement (Aptalis Pharma Inc)", "score": 23.1081447601, "published": true}], "snippet": "Aptalis shall provide to Strakan copies of all substantive or material information with respect to its activities under the Development Plan, including clinical data compiled with respect to the Product and all information and data filed with * Confidential treatment requested. any Regulatory Authority relating to the Supplemental Studies, as soon as reasonably practicable after such information, data or results become available or compiled, including any drafts and final versions of any study reports (the \u201cDevelopment Data\u201d).", "snippet_links": [{"key": "copies-of-all", "type": "definition", "offset": [33, 46]}, {"key": "material-information", "type": "definition", "offset": [62, 82]}, {"key": "with-respect-to", "type": "clause", "offset": [83, 98]}, {"key": "activities-under", "type": "clause", "offset": [103, 119]}, {"key": "the-development-plan", "type": "clause", "offset": [120, 140]}, {"key": "clinical-data", "type": "definition", "offset": [152, 165]}, {"key": "the-product", "type": "definition", "offset": [191, 202]}, {"key": "information-and-data", "type": "clause", "offset": [211, 231]}, {"key": "confidential-treatment-requested", "type": "clause", "offset": [245, 277]}, {"key": "regulatory-authority", "type": "definition", "offset": [283, 303]}, {"key": "relating-to", "type": "definition", "offset": [304, 315]}, {"key": "supplemental-studies", "type": "clause", "offset": [320, 340]}, {"key": "such-information", "type": "definition", "offset": [382, 398]}, {"key": "study-reports", "type": "clause", "offset": [493, 506]}], "size": 3, "hash": "917a4660191db89f8a24dfaf3b13ce6f", "id": 6}, {"samples": [{"hash": "kD2dgLVVlBK", "uri": "/contracts/kD2dgLVVlBK#development-data", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}, {"hash": "2rLQVGEgVCt", "uri": "/contracts/2rLQVGEgVCt#development-data", "label": "Exclusive License Agreement (Allarity Therapeutics, Inc.)", "score": 33.3723487854, "published": true}], "snippet": "(a) Each Party shall solely own all data, records and reports generated by or on behalf of such Party, its Affiliates or Sublicensees (with respect to Oncoheroes), in the non-clinical and clinical Development of the Product (the \u201cProduct Data\u201d); provided, that neither Party is deemed to conduct Development of the Product on behalf of the other Party. Notwithstanding any provision of this Agreement to the contrary, Product Data that a Party is required to deliver to the other Party under this Agreement shall be limited to Product Data that is (a) Controlled by such Party and (b) that is necessary or reasonably useful to support the Development, Regulatory Approval or Commercialization of the Products.\n(b) Each Party, shall, on a Calendar Quarterly basis and at no charge to the other Party, as permitted under Applicable Law (including GCP), provide the other Party with a summary of all Product Data not previously transferred under this Section 4.5. Allarity may disclose and provide copies of such Product Data Controlled by Oncoheroes to Allarity\u2019s Affiliates and Third Party licensees that have agreed in writing to share development data with Allarity and Oncoheroes on terms substantially similar to the terms of this Section 4.5. Oncoheroes may disclose and provide copies of such Product Data Controlled by Allarity to Oncoheroes\u2019 Affiliates and Sublicensees that have agreed in writing to share development data with Allarity and Oncoheroes on terms substantially similar to the terms of this Section 4.5.", "snippet_links": [{"key": "each-party", "type": "definition", "offset": [4, 14]}, {"key": "records-and-reports", "type": "definition", "offset": [42, 61]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [72, 90]}, {"key": "such-party", "type": "clause", "offset": [91, 101]}, {"key": "with-respect-to", "type": "clause", "offset": [135, 150]}, {"key": "the-non", "type": "clause", "offset": [167, 174]}, {"key": "development-of-the-product", "type": "clause", "offset": [197, 223]}, {"key": "product-data", "type": "definition", "offset": [230, 242]}, {"key": "neither-party", "type": "definition", "offset": [261, 274]}, {"key": "other-party", "type": "clause", "offset": [340, 351]}, {"key": "agreement-to", "type": "definition", "offset": [391, 403]}, {"key": "a-party", "type": "clause", "offset": [436, 443]}, {"key": "deliver-to", "type": "definition", "offset": [459, 469]}, {"key": "the-development", "type": "clause", "offset": [635, 650]}, {"key": "regulatory-approval", "type": "clause", "offset": [652, 671]}, {"key": "commercialization-of-the-products", "type": "clause", "offset": [675, 708]}, {"key": "quarterly-basis", "type": "definition", "offset": [747, 762]}, {"key": "no-charge", "type": "clause", "offset": [770, 779]}, {"key": "applicable-law", "type": "clause", "offset": [819, 833]}, {"key": "provide-the", "type": "clause", "offset": [851, 862]}, {"key": "section-45", "type": "clause", "offset": [948, 959]}, {"key": "copies-of", "type": "definition", "offset": [995, 1004]}, {"key": "third-party-licensees", "type": "definition", "offset": [1077, 1098]}, {"key": "have-agreed", "type": "clause", "offset": [1104, 1115]}, {"key": "in-writing", "type": "definition", "offset": [1116, 1126]}, {"key": "similar-to", "type": "definition", "offset": [1205, 1215]}, {"key": "terms-of", "type": "definition", "offset": [1220, 1228]}, {"key": "affiliates-and-sublicensees", "type": "clause", "offset": [1349, 1376]}], "size": 3, "hash": "a8f3818753298ecd4c821c44eb3cad07", "id": 7}, {"samples": [{"hash": "lRot0yqpvz0", "uri": "/contracts/lRot0yqpvz0#development-data", "label": "License Agreement (Braeburn Pharmaceuticals, Inc.)", "score": 27.9952087402, "published": true}, {"hash": "aBxKFUnrWCS", "uri": "/contracts/aBxKFUnrWCS#development-data", "label": "License Agreement (Braeburn Pharmaceuticals, Inc.)", "score": 27.937713623, "published": true}], "snippet": "(a) To the extent permitted by law, Braeburn grants Camurus, its Affiliates and licensees the right to use and cross-reference any Development Data and regulatory filings, including INDs, NDAs and Regulatory Approvals, Controlled by Braeburn, its Affiliates or Sublicensees as may be necessary or useful for Camurus, its Affiliates and licensees to make regulatory filings for (i) the Products, and (ii) any other products not being a Competing Product in the Territory, to the extent such Development Data and regulatory filings, including INDs, NDAs and Regulatory Approvals, relate to Cam urns Platform IP. Braeburn shall give Camurus, its Affiliates and licensees reasonable access (including the right to copy where reasonably required) to a copy of (i) the complete NDA for the Products filed by Braeburn, its Affiliates or Sublicensees with FDA or any other applicable Regulatory Authorities in the Licensed Territory, and (ii) Regulatory Approvals for the Products granted by FDA or any other applicable Regulatory Authorities in the Licensed Territory.\n(b) To the extent permitted by law, Camurus grants Braeburn, its Affiliates and Sublicensees the right to use and cross-reference any Development Data and regulatory filings, including INDs, NDAs and Regulatory Approvals, Controlled by Camurus, its Affiliates or licensees as may be necessary or useful for Braeburn, its Affiliates and Sublicensees to make regulatory filings for the Products in the Licensed Territory. Camurus shall give Braeburn, its Affiliates and Sublicensees reasonable access (including the right to copy where reasonably required) to a copy of (i) the complete NDA for the Products filed by Camurus, its Affiliates or licensees with the EMA or any other applicable Regulatory Authorities in the Camurus Territory, and (ii) Regulatory Approvals for the Products granted to Camurus, its Affiliates or its licensees by the EMA or any other applicable Regulatory Authorities in the Camurus Territory. Notwithstanding the foregoing, Camurus shall not be required to provide Braeburn, its Affiliates and Sublicensees the rights described in this Section 3.9, if Camurus is restricted from doing so pursuant to an agreement with a Third Party in effect prior to the Effective Date.", "snippet_links": [{"key": "to-the-extent-permitted-by-law", "type": "clause", "offset": [4, 34]}, {"key": "right-to-use", "type": "definition", "offset": [94, 106]}, {"key": "regulatory-filings", "type": "definition", "offset": [152, 170]}, {"key": "regulatory-approvals", "type": "clause", "offset": [197, 217]}, {"key": "the-products", "type": "clause", "offset": [381, 393]}, {"key": "other-products", "type": "definition", "offset": [408, 422]}, {"key": "competing-product", "type": "definition", "offset": [435, 452]}, {"key": "in-the-territory", "type": "clause", "offset": [453, 469]}, {"key": "relate-to", "type": "definition", "offset": [578, 587]}, {"key": "platform-ip", "type": "definition", "offset": [597, 608]}, {"key": "reasonable-access", "type": "definition", "offset": [668, 685]}, {"key": "right-to-copy", "type": "clause", "offset": [701, 714]}, {"key": "where-reasonably-required", "type": "clause", "offset": [715, 740]}, {"key": "a-copy-of", "type": "clause", "offset": [745, 754]}, {"key": "applicable-regulatory-authorities", "type": "definition", "offset": [865, 898]}, {"key": "licensed-territory", "type": "definition", "offset": [906, 924]}, {"key": "granted-by", "type": "definition", "offset": [973, 983]}, {"key": "affiliates-and-sublicensees", "type": "clause", "offset": [1127, 1154]}, {"key": "granted-to", "type": "clause", "offset": [1847, 1857]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1983, 2012]}, {"key": "to-provide", "type": "clause", "offset": [2044, 2054]}, {"key": "rights-described", "type": "clause", "offset": [2101, 2117]}, {"key": "section-39", "type": "clause", "offset": [2126, 2137]}, {"key": "pursuant-to-an-agreement", "type": "definition", "offset": [2178, 2202]}, {"key": "a-third-party", "type": "clause", "offset": [2208, 2221]}, {"key": "in-effect", "type": "definition", "offset": [2222, 2231]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [2232, 2259]}], "size": 3, "hash": "3bcaaeda0d8d55d0a00495b2c7336dba", "id": 8}, {"samples": [{"hash": "ifZh6UHg9uA", "uri": "/contracts/ifZh6UHg9uA#development-data", "label": "License Agreement (Ignyta, Inc.)", "score": 26.0787124634, "published": true}, {"hash": "8Yy19g3itQ6", "uri": "/contracts/8Yy19g3itQ6#development-data", "label": "License Agreement (Ignyta, Inc.)", "score": 25.848733902, "published": true}], "snippet": "(a) Promptly after the Effective Date, Nerviano shall transfer to Ignyta all existing Development Data and during the term of this Agreement Nerviano shall promptly and consistently transfer to Ignyta all Development Data as and when generated or developed. Ignyta shall be the sole owner of the Development Data and Nerviano does and hereby assigns to Ignyta all of its right, title and interest therein.\n(b) Both Parties shall develop and maintain the Development Data, related records, documents and raw data in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the development of the APIs and Products.", "snippet_links": [{"key": "after-the-effective-date", "type": "clause", "offset": [13, 37]}, {"key": "transfer-to", "type": "clause", "offset": [54, 65]}, {"key": "existing-development", "type": "definition", "offset": [77, 97]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [107, 140]}, {"key": "sole-owner", "type": "definition", "offset": [278, 288]}, {"key": "the-development", "type": "clause", "offset": [292, 307]}, {"key": "title-and-interest", "type": "clause", "offset": [378, 396]}, {"key": "both-parties", "type": "definition", "offset": [410, 422]}, {"key": "related-records", "type": "definition", "offset": [472, 487]}, {"key": "raw-data", "type": "definition", "offset": [503, 511]}, {"key": "sufficient-detail", "type": "clause", "offset": [515, 532]}, {"key": "all-work", "type": "clause", "offset": [588, 596]}, {"key": "results-achieved", "type": "clause", "offset": [606, 622]}, {"key": "development-of-the", "type": "clause", "offset": [630, 648]}], "size": 3, "hash": "bc231b8ac4fa7600460f8b402142241b", "id": 9}, {"samples": [{"hash": "fyU9yu51jLI", "uri": "/contracts/fyU9yu51jLI#development-data", "label": "Fourth Amendment and Restatement Agreement (CureVac N.V.)", "score": 33.3203277588, "published": true}], "snippet": "Except to the extent the Development Data enter the public domain pursuant to Section 11.7, the Development Data shall be treated as Confidential Information of the Parties. Each Party may use, and allow its Affiliates to use, the Development Data for the purpose of \u200b \u200b obtaining adequate protection and prosecution of their respective Know-How and Patent Rights, or as provided for otherwise in accordance with this Agreement, provided that in each case it provides the other Party with prior written notice of its intent to use the Development Data for such purpose. The other Party may, within a reasonable time following receipt of such notice, request the notifying Party to delay the use of the Development Data, in order to safeguard the protection and prosecution of other Know-How and Patent Rights. Following such request, the Parties shall cooperate in good faith to align the protection and prosecution of each Party\u2019s Know-How and Patent Rights. For the avoidance of doubt, the terms and conditions of this Article 9 shall govern the intellectual property rights of the Parties in the Development Data.", "snippet_links": [{"key": "except-to-the-extent", "type": "clause", "offset": [0, 20]}, {"key": "the-development", "type": "clause", "offset": [21, 36]}, {"key": "public-domain", "type": "definition", "offset": [52, 65]}, {"key": "pursuant-to-section", "type": "definition", "offset": [66, 85]}, {"key": "confidential-information-of-the-parties", "type": "clause", "offset": [133, 172]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [248, 266]}, {"key": "adequate-protection", "type": "clause", "offset": [281, 300]}, {"key": "patent-rights", "type": "definition", "offset": [350, 363]}, {"key": "in-accordance-with", "type": "definition", "offset": [394, 412]}, {"key": "this-agreement", "type": "clause", "offset": [413, 427]}, {"key": "provided-that", "type": "clause", "offset": [429, 442]}, {"key": "each-case", "type": "definition", "offset": [446, 455]}, {"key": "other-party", "type": "clause", "offset": [472, 483]}, {"key": "notice-of", "type": "definition", "offset": [503, 512]}, {"key": "intent-to-use", "type": "clause", "offset": [517, 530]}, {"key": "reasonable-time", "type": "clause", "offset": [600, 615]}, {"key": "receipt-of", "type": "clause", "offset": [626, 636]}, {"key": "notifying-party", "type": "clause", "offset": [662, 677]}, {"key": "in-order-to", "type": "clause", "offset": [720, 731]}, {"key": "the-parties-shall", "type": "clause", "offset": [834, 851]}, {"key": "in-good-faith", "type": "definition", "offset": [862, 875]}, {"key": "of-each-party", "type": "clause", "offset": [916, 929]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [960, 986]}, {"key": "article-9", "type": "definition", "offset": [1021, 1030]}, {"key": "intellectual-property-rights-of-the-parties", "type": "clause", "offset": [1048, 1091]}], "size": 3, "hash": "8f143bb80d07592fd04322fefbccb088", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhlkZXZlbG9wbWVudC1kYXRhIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"children": [["use", "Use"], ["ownership", "Ownership"], ["obligations-of-khk", "Obligations of KHK"], ["obligations-of-ugnx", "Obligations of UGNX"], ["disclosure", "Disclosure"]], "parents": [["development", "Development"], ["development-of-product", "Development of Product"], ["term-and-termination", "Term and Termination"], ["intellectual-property", "Intellectual Property"], ["effect-of-termination", "Effect of Termination"]], "title": "Development Data", "size": 86, "id": "development-data", "related": [["development-records", "Development Records", "Development Records"], ["development-work", "Development Work", "Development Work"], ["development-phase", "Development Phase", "Development Phase"], ["commercialization-reports", "Commercialization Reports", "Commercialization Reports"], ["development-program", "Development Program", "Development Program"]], "related_snippets": [], "updated": "2025-08-08T05:51:10+00:00"}, "json": true, "cursor": ""}}